Cytek Biosciences prelim Q4 revenue beats estimates

Overview

• Cell analysis firm's preliminary Q4 revenue rose 8% yr/yr, beating analyst expectations

• Company's growth driven by services, reagents, and instrument sales in Asia Pacific, US, EMEA

Outlook

• Cytek expects its total revenue for the full year 2025 to be approximately $201 million

• Company sees sustainable growth and profitability in flow cytometry market

Result Drivers

• SERVICES AND REAGENTS - Strong growth in services and reagents contributed significantly to Q4 revenue increase

• ASIA PACIFIC INSTRUMENT SALES - Notable growth in instrument sales in Asia Pacific region supported revenue growth

• EMEA INSTRUMENT SALES - Return to positive growth in EMEA instrument sales contributed to overall revenue growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.75, about 5.5% above its January 9 closing price of $5.45

Press Release: ID:nGNX3Yh35w

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.